A Randomized, Multicenter, Double-blind Phase 3 Study Of Pd-0332991 (Oral Cdk 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With Er (+), Her2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease

Trial Profile

A Randomized, Multicenter, Double-blind Phase 3 Study Of Pd-0332991 (Oral Cdk 4/6 Inhibitor) Plus Letrozole Versus Placebo Plus Letrozole For The Treatment Of Postmenopausal Women With Er (+), Her2 (-) Breast Cancer Who Have Not Received Any Prior Systemic Anti Cancer Treatment For Advanced Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Letrozole (Primary) ; Palbociclib (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms PALOMA-2
  • Sponsors Pfizer
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 05 Jun 2017 Status changed from suspended to active, no longer recruiting.
    • 02 Jun 2017 Results of subgroup (visceral and nonvisceral disease, prior HT and no prior HT, DFI less than 12 months and DFI less than or equal to12 months, prior CT and no prior CT) analyses, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top